RNA sequencing has become an essential tool for understanding how genes function in health and disease. In addition to measuring normal gene expression, it can also detect unusual RNA molecules called chimeric RNAs, which are formed when parts of two different genes become joined together through genomic rearrangements or abnormal RNA splicing. These hybrid molecules are attracting growing attention as potential biomarkers and therapeutic targets.

Researchers at Bar Ilan University describe an integrated platform that combines the ChiTaRS 8.0 database with the ChiTaH analysis pipeline to improve the identification and interpretation of chimeric RNAs from RNA sequencing data.

ChiTaRS 8.0 is one of the largest resources available for chimeric RNA research, containing more than 47,000 human chimeric RNAs along with information about genomic breakpoints and potential drug targets. The companion ChiTaH pipeline analyzes RNA sequencing data using multiple validation steps to distinguish genuine chimeric RNAs from sequencing artifacts. These include reference based fusion detection, genome alignment, gene compatibility testing, and protein domain analysis.

The researchers demonstrated the platform using hundreds of patient samples from individuals with glioblastoma, oral squamous cell carcinoma, Alzheimer’s disease, and healthy volunteers. Their analyses identified disease associated chimeric RNAs that were not present in existing databases and revealed that many exhibit tissue specific expression patterns.

One particularly promising application involves liquid biopsy. By analyzing cerebrospinal fluid from patients with Alzheimer’s disease, the researchers identified unique chimeric RNAs, including ENO1-MCUR1 and APOE-APOE, that were absent in healthy individuals. These molecules were linked to biological pathways involved in neurotransmission and amyloid processing, suggesting they could serve as early biomarkers for disease detection.

Beyond identifying biomarkers, the platform also supports drug discovery. By integrating artificial intelligence, protein interaction analysis, clinical information, and multiomics datasets, the system helps researchers identify potential therapeutic targets while supporting patient stratification for precision medicine.

As RNA sequencing continues to generate increasingly complex datasets, computational tools such as ChiTaRS and ChiTaH are becoming essential for extracting clinically meaningful information. Their ability to identify previously unrecognized chimeric RNAs could improve disease diagnosis, guide targeted therapies, and deepen our understanding of cancer and neurodegenerative disorders.

Availability – Chimeric Transcripts and RNA-Sequencing database version 8.0 (ChiTaRS 8.0) is available at: http://biosrv.org/chitars